Significantly lower risk is seen for hospitalization and cases. 4 studies from 4 independent teams in 4 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 39% [14‑56%] lower risk. Results are similar for Randomized Controlled Trials and higher quality studies.
Currently there is limited data, with only 37 control events for the most serious outcome in trials to date.
2 RCTs with 664 patients have not reported results (up to 2 years late)1,2.
Montelukast has a boxed warning for neuropsychiatric side effects3.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. Montelukast currently has no early treatment studies. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Jan 2025, preprint, 1 author.
